Axon Enterprise, Inc $AXON Stock Bought by Kestra Advisory Services LLC

Kestra Advisory Services LLC lifted its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 30,838.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,188,963 shares of the biotechnology company’s stock after acquiring an additional 1,185,120 shares during the period. Axon Enterprise makes up 1.4% of Kestra Advisory Services LLC’s portfolio, making the stock its 7th largest holding. Kestra Advisory Services LLC’s holdings in Axon Enterprise were worth $502,361,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. State Street Corp increased its position in Axon Enterprise by 5,700.2% during the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock worth $119,724,905,000 after acquiring an additional 209,879,882 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Axon Enterprise by 18,050.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock valued at $7,400,094,000 after purchasing an additional 13,127,348 shares during the period. BlackRock Inc. boosted its holdings in Axon Enterprise by 4.3% in the 2nd quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock valued at $4,672,432,000 after purchasing an additional 345,365 shares during the period. Robeco Institutional Asset Management B.V. boosted its holdings in Axon Enterprise by 391,214.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock valued at $2,952,943,000 after purchasing an additional 6,987,098 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Axon Enterprise by 8,432.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock worth $1,983,414,000 after purchasing an additional 3,496,493 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Buying and Selling

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 9,605 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the sale, the insider directly owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This represents a 8.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president directly owned 296,974 shares in the company, valued at $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,397 shares of company stock worth $21,234,034 in the last quarter. Corporate insiders own 4.20% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon reported record Q3 revenue of $909 million, up 28% year over year, and returned to net income. Adjusted EBITDA rose 33% to $236 million. Axon Q3 results
• Positive Sentiment: Growth in newer offerings was strong: Drone as First Responder software and services revenue grew 43%, Platform Solutions revenue climbed 106%, and AI annual recurring revenue exceeded $100 million. Axon Q3 results
• Positive Sentiment: Axon invested an additional $1.2 billion in Skydio, raising its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The deal could strengthen Axon’s drone-response offering, though it requires substantial capital. Axon Skydio investment
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of about $909 million both missed analyst estimates, despite solid year-over-year growth. Q3 earnings and revenue miss
• Negative Sentiment: Axon’s Q4 revenue outlook of $990 million–$1.0 billion was below the roughly $1.1 billion consensus, while its full-year 2026 revenue outlook of $3.6 billion also trailed expectations of about $3.7 billion. Revenue outlook and Skydio investment
• Negative Sentiment: Zacks Research downgraded Axon from “strong buy” to “hold.” A lawsuit over the company’s AI-powered license-plate-reader network also presents potential legal uncertainty. License plate reader lawsuit

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $382.56 on Friday. The firm has a market capitalization of $31.08 billion, a price-to-earnings ratio of 158.74, a PEG ratio of 8.06 and a beta of 1.48. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $665.07. The business has a fifty day simple moving average of $447.49 and a 200 day simple moving average of $476.73. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The business had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. During the same quarter in the prior year, the firm earned $1.17 EPS. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. Sell-side analysts expect that Axon Enterprise, Inc will post 2.10 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on AXON shares. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday. UBS Group increased their target price on shares of Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Tuesday. Barclays lifted their target price on Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Finally, TD Cowen lowered their price target on Axon Enterprise from $825.00 to $800.00 and set a “buy” rating on the stock in a research note on Monday, October 26th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $688.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and connected products for public safety organizations. The company’s portfolio includes TASER conducted-energy weapons, body-worn cameras, in-car cameras, and related hardware designed to support law enforcement, corrections, security, and other emergency-response professionals.

Axon also provides cloud-based software for managing digital evidence, records, workflows, real-time operations, investigations, and communications. Its platform is intended to connect hardware, software, and services across the public-safety ecosystem, helping agencies collect, store, analyze, and share operational information.

The company was founded in 1993 as TASER International by Rick Smith and Tom Smith and adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into a broader technology platform.